drugset
drugset / Trial / NCT06054698

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

NCT06054698 ↗

Phase 2 Completed 61 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the efficacy of HRS9531 injection compared with placebo in weight reduction in overweight or obese subjects after 36 weeks of treatment.

Timeline

Start
2023-10-16
Primary completion
2024-09-09
Completion
2024-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown — —

Indications

obesity disorder